Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | MDGL |
---|---|---|
09:32 ET | 1744 | 216.93 |
09:34 ET | 480 | 215.46 |
09:38 ET | 450 | 218.4597 |
09:41 ET | 100 | 216.9 |
09:45 ET | 2200 | 217.39 |
09:50 ET | 256 | 216.635 |
09:52 ET | 200 | 215.77 |
09:54 ET | 100 | 216 |
09:56 ET | 150 | 216 |
09:57 ET | 1324 | 214.6 |
09:59 ET | 1213 | 214.685 |
10:01 ET | 1276 | 216.165 |
10:03 ET | 524 | 215.33 |
10:06 ET | 1102 | 215.97 |
10:10 ET | 300 | 214.755 |
10:14 ET | 500 | 215.03 |
10:15 ET | 200 | 214.47 |
10:17 ET | 800 | 214.41 |
10:19 ET | 981 | 214.875 |
10:24 ET | 100 | 214.925 |
10:26 ET | 100 | 214.945 |
10:30 ET | 300 | 214.27 |
10:35 ET | 244 | 214.45 |
10:37 ET | 800 | 214.71 |
10:42 ET | 100 | 214.0001 |
10:50 ET | 1388 | 213.815 |
10:55 ET | 1300 | 212.99 |
10:57 ET | 200 | 212.9194 |
11:00 ET | 1100 | 211.6 |
11:02 ET | 300 | 211.6628 |
11:04 ET | 400 | 212.22 |
11:06 ET | 200 | 212.63 |
11:08 ET | 500 | 213.17 |
11:09 ET | 200 | 213.31 |
11:11 ET | 111 | 213.94 |
11:13 ET | 787 | 214.32 |
11:15 ET | 200 | 214.39 |
11:18 ET | 409 | 213.995 |
11:20 ET | 149 | 214.074 |
11:27 ET | 200 | 214.1442 |
11:31 ET | 100 | 214.52 |
11:33 ET | 100 | 214.57 |
11:38 ET | 200 | 214.6833 |
11:42 ET | 6523 | 213.96 |
11:44 ET | 100 | 214.17 |
11:45 ET | 200 | 213.51 |
11:47 ET | 100 | 214.28 |
12:03 ET | 100 | 213.8 |
12:05 ET | 253 | 213.82 |
12:07 ET | 100 | 214.01 |
12:18 ET | 100 | 213.37 |
12:23 ET | 3325 | 212.39 |
12:25 ET | 600 | 212.49 |
12:27 ET | 2126 | 212.82 |
12:32 ET | 110 | 212.6601 |
12:38 ET | 925 | 212.5 |
12:39 ET | 500 | 212.815 |
12:43 ET | 100 | 212.76 |
12:50 ET | 100 | 213.48 |
12:52 ET | 100 | 212.8101 |
12:57 ET | 200 | 213.09 |
01:01 ET | 224 | 213.205 |
01:10 ET | 290 | 212.8 |
01:15 ET | 400 | 211.8 |
01:17 ET | 200 | 211.97 |
01:19 ET | 200 | 212.11 |
01:26 ET | 250 | 211.96 |
01:30 ET | 1800 | 211.375 |
01:32 ET | 400 | 211.435 |
01:42 ET | 200 | 211.285 |
01:46 ET | 400 | 211 |
01:48 ET | 400 | 210.945 |
01:50 ET | 620 | 210.945 |
01:51 ET | 1223 | 211.405 |
01:53 ET | 150 | 211.125 |
01:55 ET | 700 | 211 |
01:57 ET | 281 | 211.5187 |
02:00 ET | 100 | 211.58 |
02:02 ET | 349 | 211.91 |
02:04 ET | 477 | 211.57 |
02:06 ET | 100 | 210.775 |
02:09 ET | 2300 | 211.095 |
02:11 ET | 2200 | 210.96 |
02:13 ET | 500 | 211.15 |
02:15 ET | 300 | 211.68 |
02:18 ET | 985 | 211.69 |
02:22 ET | 400 | 211.75 |
02:26 ET | 450 | 211.82 |
02:29 ET | 200 | 211.825 |
02:33 ET | 204 | 211.871 |
02:36 ET | 200 | 211.925 |
02:38 ET | 100 | 211.98 |
02:40 ET | 1200 | 212.005 |
02:42 ET | 100 | 212.13 |
02:44 ET | 100 | 212.405 |
02:47 ET | 700 | 212.18 |
02:51 ET | 200 | 211.97 |
02:54 ET | 3798 | 213.17 |
02:56 ET | 100 | 213.5 |
03:00 ET | 1750 | 212.85 |
03:03 ET | 200 | 213.275 |
03:05 ET | 100 | 213.265 |
03:07 ET | 100 | 213.51 |
03:12 ET | 500 | 213.93 |
03:18 ET | 1308 | 213.555 |
03:20 ET | 203 | 214.31 |
03:21 ET | 100 | 213.95 |
03:23 ET | 700 | 214.065 |
03:25 ET | 138 | 213.81 |
03:27 ET | 100 | 213.95 |
03:30 ET | 1329 | 214.02 |
03:32 ET | 2250 | 214.34 |
03:36 ET | 400 | 214.185 |
03:38 ET | 458 | 213.71 |
03:39 ET | 1810 | 213.93 |
03:43 ET | 570 | 213.8 |
03:45 ET | 300 | 213.255 |
03:48 ET | 1500 | 213.82 |
03:50 ET | 100 | 213.67 |
03:52 ET | 1085 | 213.745 |
03:54 ET | 200 | 213.77 |
03:56 ET | 18771 | 214.09 |
03:57 ET | 3808 | 213.685 |
03:59 ET | 56591 | 213.9 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Madrigal Pharmaceuticals Inc | 4.7B | -8.4x | --- |
Biohaven Ltd | 4.7B | -5.6x | --- |
BridgeBio Pharma Inc | 4.6B | -9.3x | --- |
Immunovant Inc | 4.2B | -14.8x | --- |
Crinetics Pharmaceuticals Inc | 4.0B | -13.4x | --- |
Avidity Biosciences Inc | 5.4B | -14.3x | --- |
Madrigal Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in pursuing novel therapeutics for non-alcoholic steatohepatitis (NASH). The Company's product candidate, resmetirom, is a once-daily, oral, liver-directed thyroid hormone receptor-β (THR-β) agonist designed to target key underlying causes of NASH. NASH is a more advanced form of non-alcoholic fatty liver disease (NAFLD). The Company’s clinical development program includes MAESTRO-NASH, MAESTRO-NAFLD-1, and MAESTRO-NASH OUTCOMES.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $4.7B |
---|---|
Revenue (TTM) | $14.6M |
Shares Outstanding | 21.7M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | -0.44 |
EPS | $-25.50 |
Book Value | $20.39 |
P/E Ratio | -8.4x |
Price/Sales (TTM) | 320.7 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -3,622.65% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.